François-Clément Bidard, Head of Center for Clinical Investigation CIC-2501 at Inserm, shared on LinkedIn:
“SERENA-6 updated data published today (Bastille day) in Lancet Oncology (free link for 50 days).
This very detailled paper agregates
- ctDNA screening data (mini-oral ESMO breast 26)
- updated efficacy + safety + QoL data from the 3rd data cut-off (oral ASCO 26)
- and many other original results reported in the supp appendix (eg TFST, TSST, or even ESR1m VAF at detection in the screening step, in randomized vs non-randomized patients – the picture of this post).”
Title: Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
Authors: Nicholas C. Turner, Erica L. Mayer, Yeon Hee Park, Wolfgang Janni, Cynthia Ma, Massimo Cristofanilli, Giampaolo Bianchini, Kevin Kalinsky, Hiroji Iwata, Stephen Chia, Adam M. Brufsky, Peter A. Fasching, Zbigniew Nowecki, Javier Pascual, Nuri Karadurmus, Einav Gal-Yam, Wei-Pang Chung, Seock-Ah Im, Alberto Zambelli, Florence Dalenc, François-Clément Bidard
Read the full article.
You can also read:
